Bio-Thera Reports the Initiation of P-III Clinical Trial for BAT2506 (biosimilar- golimumab)
Shots:
- The company has initiated a P-III clinical study to evaluate the efficacy and safety of BAT2506 vs Simponi in ~ 480 volunteers with PsA. Simponi is approved for moderately to severely active RA- active PsA- active AS & UC
- BAT2506 is the 3rd proposed biosimilar of the company to enter a global P-III study
- Bio-Thera is developing other proposed biosimilars- including a bevacizumab & tocilizumab biosimilar that have completed P-III trial and is also pursuing biosimilar versions of ustekinumab- mepolizumab and dupilumab
| Ref: Business Wire | Image: Business Wire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com